Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Optimi Health Corp C.OPTI

Alternate Symbol(s):  OPTHF

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable... see more

Recent & Breaking News (CSE:OPTI)

Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia

Newsfile October 23, 2024

Optimi Health Announces Leadership Transition

Newsfile October 21, 2024

Optimi will test its psilocybin on frontline healthcare workers

Trevor Abes  August 28, 2024

Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial

Newsfile August 28, 2024

Optimi Health ships first MDMA capsules to Australia to treat PTSD

Jocelyn Aspa August 16, 2024

Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment

Newsfile August 16, 2024

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

GlobeNewswire August 13, 2024

Optimi Health Announces Non-Brokered Private Placement

Newsfile August 7, 2024

Optimi Health to enter Asia with psilocybin research collaboration

Jonathon Brown July 23, 2024

Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research

Newsfile July 23, 2024

Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists

Newsfile June 27, 2024

Optimi Health makes commercial entry into Australia

Jonathon Brown June 25, 2024

Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia's Authorised Prescriber Scheme

Newsfile June 25, 2024

Optimi Health completes first MDMA shipment to Israel

Jonathon Brown June 11, 2024

Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID

Newsfile June 11, 2024

Optimi Health cleared to supply MDMA and psilocybin worldwide

Trevor Abes  June 4, 2024

Canadian Investment Regulatory Organization Trade Resumption - OPTI

Canada NewsWire June 3, 2024

Optimi Health Awarded Drug Establishment Licence From Health Canada

PR Newswire June 3, 2024

Canadian Investment Regulatory Organization Trading Halt - OPTI

Canada NewsWire June 3, 2024

Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing

PR Newswire May 31, 2024